-
1.发明授权PYRAZOLO-HETEROARYL COMPOUNDS USEFUL TO TREAT TNF-ALPHA AND IL-1 MEDIATED DISEASES 有权吡唑并嘧啶杂芳基化合物用于治疗TNF-α和IL-1介导的疾病
公开(公告)号：EP1833477B1
公开(公告)日：2010-06-02
申请号：EP05822740.6
申请日：2005-12-14
申请人： Novartis AG , Novartis Pharma GmbH
发明人： RÉVÉSZ, Lászlo
IPC分类号： A61K31/4162 , C07D471/04 , C07D487/04 , A61K31/4985 , A61K31/519 , A61P29/00
CPC分类号： C07D471/04 , C07D487/04
摘要： A compound of formula (I) wherein the groups R1-R4, X and Y are as defined in the specification, useful to treat TNF-Alpha and IL-1 mediated diseases.
-
2.发明公开PYRAZOLO-HETEROARYL COMPOUNDS USEFUL TO TREAT TNF-ALPHA AND IL-1 MEDIATED DISEASES 有权吡唑并嘧啶杂芳基化合物用于治疗TNF-α和IL-1介导的疾病
公开(公告)号：EP1833477A1
公开(公告)日：2007-09-19
申请号：EP05822740.6
申请日：2005-12-14
申请人： Novartis AG , NOVARTIS-PHARMA GMBH
发明人： RÉVÉSZ, Lászlo
IPC分类号： A61K31/4162 , C07D471/04 , C07D487/04 , A61K31/4985 , A61K31/519 , A61P29/00
CPC分类号： C07D471/04 , C07D487/04
摘要： A compound of formula (I) wherein the groups R1-R4, X and Y are as defined in the specification, useful to treat TNF-Alpha and IL-1 mediated diseases.
-
公开(公告)号：EP2064212A1
公开(公告)日：2009-06-03
申请号：EP07801933.8
申请日：2007-08-28
申请人： NOVARTIS AG
IPC分类号： C07D471/04 , C07D471/14 , C07D498/14 , A61K31/5365 , A61P37/00
CPC分类号： C07D471/04 , C07D471/14 , C07D498/14
摘要： A compound of formula (I) or a pharmaceutically acceptable salt or prodrug ester thereof: wherein the groups R1, R2, R3, R7 and X are as defined in the specification.
-
公开(公告)号：EP2178874A1
公开(公告)日：2010-04-28
申请号：EP08786115.9
申请日：2008-07-14
申请人： Novartis AG
发明人： SCHLAPBACH, Achim , RÉVÉSZ, Lászlo , KOCH, Guido
IPC分类号： C07D471/14 , C07D471/20 , C07D471/22 , C07D487/22 , C07D491/22 , A61K31/4375 , A61K31/437 , A61P9/00 , A61P29/00 , A61P37/00
CPC分类号： C07D471/14 , C07D471/20 , C07D471/22 , C07D487/22 , C07D491/22
摘要： The present invention describes tetracyclic compounds of formula (IA) or (IB), wherein the symbols R, X, A, Y, R2, R3 and D are as defined in the specification, their use in the treatment of certain diseases, e.g. depending on MK-2 or TNF activity, and ways of manufacturing them.
-
公开(公告)号：EP1615898B1
公开(公告)日：2014-10-29
申请号：EP04726485.8
申请日：2004-04-08
申请人： Novartis AG , Novartis Pharma GmbH
发明人： BOLLBUCK, Birgit , DENHOLM, Alastair Novartis Horsham Research Ctre. , EDER, Jörg , HERSPERGER, René , JANSER, Philipp , RÉVÉSZ, Lászlo , SCHLAPBACH, Achim , WÄLCHLI, Rudolf
IPC分类号： C07D239/42 , C07D403/04 , C07D403/10 , C07D403/14 , C07D409/04 , C07D413/10 , A61K31/506 , A61P1/00 , A61P11/00 , A61P17/00 , A61P19/00 , A61P25/00 , A61P35/00 , A61P37/00
CPC分类号： C07D239/42 , C07D403/04 , C07D403/10 , C07D403/14 , C07D409/04 , C07D409/14 , C07D413/10
-
公开(公告)号：EP1794164A2
公开(公告)日：2007-06-13
申请号：EP05737794.7
申请日：2005-04-25
申请人： Novartis AG , NOVARTIS-PHARMA GMBH
IPC分类号： C07D487/08 , C07D498/08 , A61K31/4995 , A61P37/00
CPC分类号： C07D451/14 , C07D451/04 , C07D487/08
摘要： A compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, wherein the symbols have meaning as defined, which are antagonists of CCR-1 and which find use pharmaceutically for treatment of diseases and conditions in which CCR-1 is implicated, e.g. inflammatory diseases.
-
-
-
-
-
搜索结果
6 条记录 (耗时 0.016 秒)
